Details of the Drug Combination

General Information of Drug Combination (ID: DCFH555)

• Drug Combination Name: Arfolitixorin + LY03004
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Arfolitixorin (DMIXMYK): Small molecular drug
  LY03004 (DME5TUR): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 7.59
  Bliss Independence Score: 7.59
  Loewe Additivity Score: 9.26
  LHighest Single Agent (HSA) Score: 9.27

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)